TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27154357

Group type: EXPERIMENTAL
Intervention: LY + SUN (LY2510924 20 mg SC daily + Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SUN (Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Number of subjects: 108
Study: 25978321

Group type: EXPERIMENTAL
Intervention: Training in the correct use of a satiety labelled magnitude scale (LMS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standard breakfast with 5g of viscous fibre
Number of subjects: 23
Study: 22033810

Group type: EXPERIMENTAL
Intervention: Colonic stenting followed by elective surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 39
Study: 20232413

Group type: EXPERIMENTAL
Intervention: BMT resection
Number of subjects: 242

Group type: COMPARATOR
Intervention: BMT preservation
Number of subjects: 242
Study: 18547433

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 65
Study: 15876347

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study: 11808937

Group type: EXPERIMENTAL
Intervention: Initial phlebotomy to reduce serum ferritin levels to 10 ng/ml or less followed by maintenance phlebotomy for 5 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (virological nonresponders to interferon)
Number of subjects: 25
Study: 10411862

Group type: EXPERIMENTAL
Intervention: Lovastatin alone
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Lovastatin + warfarin combination
Number of subjects: 919

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 919
Study: 8635022

Group type: EXPERIMENTAL
Intervention: Lipiodol-epirubicin (75 mg/m2)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Lipiodol-131I (750-1050 MBq)
Number of subjects: 95
Study: 2073669

Group type: EXPERIMENTAL
Intervention: Lovastatin (final average dose 70.5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 40
Study: 6845976

Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin‐3‐ol) at doses of 15 to 120 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: THIP (submaximal doses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31439091

Group type: EXPERIMENTAL
Intervention: Deproteinization with chlorine dioxide (ClO₂)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deproteinization with sodium hypochlorite (NaOCl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 0
Study: 29562558

Group type: EXPERIMENTAL
Intervention: Chin tuck against resistance exercise (CTAR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional dysphagia treatment
Number of subjects: 22
Study: 27627193

Group type: EXPERIMENTAL
Intervention: Omarigliptin 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 24724807

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (5 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22998754

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25 μg per day as cholecalciferol)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (25 μg per day as lactose)
Number of subjects: 77
Study: 21051846

Group type: EXPERIMENTAL
Intervention: Gynoflor® (lyophilized lactobacilli and 0.03 mg estriol)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metronidazole (500 mg vaginal suppositories)
Number of subjects: 46
Study: 17417917

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 14 days
Number of subjects: 59
Study: 16756030

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 57
Study: 15244246

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate, or 5-fluorouracil (CMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0
Study: 11031403

Group type: EXPERIMENTAL
Intervention: 1 week of antibiotics and a chemical matrixectomy simultaneously (group 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Antibiotics for 1 week and then a matrixectomy (group 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Matrixectomy alone (group 3)
Number of subjects: 54
Study: 8833520

Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture (IRO)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 151
Study: 1484915

Group type: EXPERIMENTAL
Intervention: Estrogen (E)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 2869001

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once a day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: oxprenolol 80 mg twice a day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: nadolol 80 mg once a day
Number of subjects: 66
Study: 30324553

Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon Alfa-2a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retreatment with Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 0
Study: 29378991

Group type: EXPERIMENTAL
Intervention: IV tramadol 100 mg (Group BT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: IV dexamethasone 8 mg (Group BD)
Number of subjects: 120
Study: 25230888

Group type: EXPERIMENTAL
Intervention: Intensive protocol (two 15-minute walks on the day of surgery)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard protocol (one 15-minute walk on the day of surgery)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intensive protocol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 66
Study: 22999636

Group type: EXPERIMENTAL
Intervention: Herpes zoster ophthalmicus (HZO) eyes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Contralateral clinically unaffected eyes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Corneal sensation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study: 21227563

Group type: EXPERIMENTAL
Intervention: 6 min of monthly practice on a voice advisory manikin
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 606
Study: 18497677

Group type: EXPERIMENTAL
Intervention: Single-dose rATG (6 mg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Divided doses rATG (1.5 mg/kg every other day for 4 days)
Number of subjects: 160
Study: 16644795

Group type: EXPERIMENTAL
Intervention: Combined PEMI of the upper and lower limbs
Number of subjects: 8

Group type: COMPARATOR
Intervention: PEMI of the upper limb alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PEMI of the lower limb (after release)
Number of subjects: 8
Study: 14646646

Group type: EXPERIMENTAL
Intervention: Unilateral saline wound irrigation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BMI > 26.3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BMI < 26.3
Number of subjects: 30
Study: 10960528

Group type: EXPERIMENTAL
Intervention: AS-24 (hypotonic storage solution)
Number of subjects: 24

Group type: COMPARATOR
Intervention: AS-3 (control storage solution)
Number of subjects: 24
Study: 8977678

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a portable desktop lamp with 300 W xenon short arc discharge source and topical 5-aminolaevulinic acid (5-ALA) applied 4 hours before irradiation, 125 J/cm2 at a fluence rate of 70 mW/cm2.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen.
Number of subjects: 40
Study: 1309410

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution, administered twice daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 6371890

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 350
Study: 30470690

Group type: EXPERIMENTAL
Intervention: FOLFIRI-ramucirumab (ram)
Number of subjects: 29
Study: 30179056

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin (40 mg m‐2) with bowel sparing IMRT (50 Gy/25#/5 wks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bowel sparing IMRT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whole pelvis + lumbar freehand V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, lower pelvis WB and FH V40 >20%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bone marrow dose volume constraints
Number of subjects: 75
Study: 26531052

Group type: EXPERIMENTAL
Intervention: Mydrane (200 μL of a combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1%)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Topical regimen (one drop each of tropicamide 0.5% and phenylephrine 10% repeated three times)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Mydrane
Number of subjects: 555

Group type: COMPARATOR
Intervention: Topical regimen
Number of subjects: 555
Study: 24781517

Group type: EXPERIMENTAL
Intervention: 2.5 mg nicotine oral soluble film
Number of subjects: 322

Group type: COMPARATOR
Intervention: 2 mg nicotine lozenge
Number of subjects: 322
Study: 22842780

Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation (PG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Back school programme (BG)
Number of subjects: 30
Study: 19535699

Group type: EXPERIMENTAL
Intervention: Helium inhalation at an end-tidal concentration of 50 vol% during ischemia-reperfusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Helium inhalation at an end-tidal concentration of 50 vol%
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (absence of helium inhalation)
Number of subjects: 8
Study: 17659458

Group type: COMPARATOR
Intervention: Ligasure technique (LT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 86
Study: 14745327

Group type: EXPERIMENTAL
Intervention: Closed suction abdominal drainage (drainage group, n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No drainage (nondrainage group, n = 52)
Number of subjects: 104
Study: 11763721

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8994935

Group type: EXPERIMENTAL
Intervention: Brain injury (female cases)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Injured controls (hospitalized for injuries other than CNS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Uninjured academic controls
Number of subjects: 99
Study: 9435773

Group type: EXPERIMENTAL
Intervention: Anti-epileptic medication added to existing drug regime
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3090314

Group type: EXPERIMENTAL
Intervention: mesna
Number of subjects: 13

Group type: COMPARATOR
Intervention: ifosfamide alone
Number of subjects: 13
Study: 31439831

Group type: EXPERIMENTAL
Intervention: 600 mg oral cannabidiol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 29263660

Group type: EXPERIMENTAL
Intervention: Long-acting β‐2 agonist (LABA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist (LAMA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clinical traits only for LABA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clinical traits only for LAMA
Number of subjects: 65
Study: 26388284

Group type: EXPERIMENTAL
Intervention: Low-sodium PD solution (125 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 338-491 mOsm/L)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard-sodium PD solution (134 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 356-509 mOsm/L)
Number of subjects: 108
Study: 24614142

Group type: EXPERIMENTAL
Intervention: GUM with scGOS/lcFOS/LCPUFAs (active group)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Cow's milk group
Number of subjects: 767

Group type: COMPARATOR
Intervention: GUM without scGOS/lcFOS/LCPUFAs (control group)
Number of subjects: 767
Study: 21719695

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation with testosterone buccal adhesive patches 2 × 30 mg/d for 8 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraplaque verapamil injections associated with testosterone administration
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intraplaque verapamil injections associated with a placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: PD patients with low bT/fT
Number of subjects: 106

Group type: COMPARATOR
Intervention: PD patients with normal bT/fT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pain and penile deformity examination
Number of subjects: 106
Study: 20178254

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a for 48 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a for 24 weeks
Number of subjects: 19
Study: 17223914

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytomegalovirus-specific T-cell immunity
Number of subjects: 0
Study: 15237762

Group type: EXPERIMENTAL
Intervention: Asthma education video game intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 119
Study: 11978676

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in men
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in women
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) prevalence in men
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) prevalence in women
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance prevalence in the youngest age group (25-34 years)
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Overall diabetes prevalence in Australia
Number of subjects: 11247

Group type: EXPERIMENTAL
Intervention: Overall prevalence of IGT or IFG in Australia
Number of subjects: 11247
Study: 10349044

Group type: EXPERIMENTAL
Intervention: Clozapine treatment with akathisia (n = 15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clozapine treatment without akathisia (n = 18)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (both groups)
Number of subjects: 33
Study: 7493423

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg) with hypoxic mixture (FiO2 = 12%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg) with normoxic mixture
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoxic mixture (FiO2 = 12%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with hypoxic mixture (FiO2 = 12%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with normoxic mixture
Number of subjects: 8
Study: 1674394

Group type: EXPERIMENTAL
Intervention: Epanolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epanolol 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epanolol 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epanolol (pooled data of 3 doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 6765503

Group type: EXPERIMENTAL
Intervention: Large doses of vitamin B6 and magnesium
Number of subjects: 44
Study: 29985978

Group type: EXPERIMENTAL
Intervention: Ivermectin-based mass drug administration (MDA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ivermectin-based MDA co-administered with azithromycin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined treatment arm (azithromycin with ivermectin)
Number of subjects: 6
Study: 28743787

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (BA)
Number of subjects: 70
Study: 26375542

Group type: EXPERIMENTAL
Intervention: Intramedullary interlocking nail
Number of subjects: 60

Group type: COMPARATOR
Intervention: Locking compression plate
Number of subjects: 60
Study: 23588058

Group type: EXPERIMENTAL
Intervention: Voice Advisory Mannequin (VAM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Instructor guidance
Number of subjects: 43
Study: 20224451

Group type: EXPERIMENTAL
Intervention: CBEX drink (containing total 2 g of carnosine and anserine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 22
Study: 19723943

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide (CP10)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 16 percent carbamide peroxide (CP16)
Number of subjects: 92
Study: 17678667

Group type: EXPERIMENTAL
Intervention: Bursts of AC electric stimulation at frequencies of 1 and 4kHz with burst durations ranging from 250 micros to 20 ms
Number of subjects: 26
Study: 15247338

Group type: EXPERIMENTAL
Intervention: nevirapine-nevirapine regimen
Number of subjects: 1844

Group type: COMPARATOR
Intervention: placebo-placebo regimen
Number of subjects: 1844

Group type: COMPARATOR
Intervention: nevirapine-placebo regimen
Number of subjects: 1844
Study: 11109970

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Micronized transvaginal progesterone
Number of subjects: 310
Study: 8815984

Group type: EXPERIMENTAL
Intervention: Choerospondias axillaris extract
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline gauze
Number of subjects: 39
Study: 1564022

Group type: EXPERIMENTAL
Intervention: 5 mg dose of methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated normal controls
Number of subjects: 0
Study: 2951114

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 0
Study: 3027193

Group type: EXPERIMENTAL
Intervention: Nucleic acid dot hybridization assay
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lymphocyte transformation assay
Number of subjects: 94
Study: 29575406

Group type: EXPERIMENTAL
Intervention: Knee-high compression socks (CS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no CS)
Number of subjects: 10
Study: 27704195

Group type: EXPERIMENTAL
Intervention: Rhomboid flap repair after fistulectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Z plasty repair after fistulectomy
Number of subjects: 40
Study: 24712501

Group type: EXPERIMENTAL
Intervention: Gratitude visit
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Three good things
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Three funny things
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Using signature strengths in a new way
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo control exercise (early memories)
Number of subjects: 163
Study: 22864398

Group type: EXPERIMENTAL
Intervention: Body weight (10-30% reduction or increase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Body weight (own body weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group × load interaction
Number of subjects: 40
Study: 20826878

Group type: EXPERIMENTAL
Intervention: Home telemonitoring of non-invasive ventilation (NIV) with a modem device (G2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 40
Study: 17964642

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the left prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the right prefrontal cortex
Number of subjects: 0
Study: 16872795

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Information group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: SDM group
Number of subjects: 67
Study: 15526500

Group type: EXPERIMENTAL
Intervention: Mix 25 (insulin lispro low mixture)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 175
Study: 10933350

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: L-arginine (7 g twice daily)
Number of subjects: 84
Study: 8725472

Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg oral dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 9
Study: 1407479

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4042547

Group type: EXPERIMENTAL
Intervention: Older subjects (63-70 years)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Young adults
Number of subjects: 9
Study: 30765809

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.15 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 30007343

Group type: EXPERIMENTAL
Intervention: Mediterranean-like dietary pattern with vitamin D3 (10 µg/d) supplements
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Control group (leaflets on healthy eating)
Number of subjects: 1294
Study: 26642244

Group type: EXPERIMENTAL
Intervention: Infinity brush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regularly used brush
Number of subjects: 60
Study: 23955516

Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannulae (HHHFNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NCPAP with Sticky Whiskers®
Number of subjects: 0

Group type: COMPARATOR
Intervention: NCPAP with Cannualaide®
Number of subjects: 0
Study: 22898365

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301